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Dear Editor, 
:HZHOFRPHWKHGHEDWHDURXQGRXUDUWLFOH³5HSOicating Health Economic Models: Firm Foundations 
RUD+RXVHRI&DUGV"´>@SXWIRUZDUGE\0F0DQXVDQG6DFK>@,QWKHLUFRPPHQWDU\0F0DQXVHW
al. criticise the original article on the grounds that it did not include a comprehensive review of the 
advantages and disadvantages of model replication. As such, it is argued that there are other benefits to 
model replication which are not discussed in the paper, making particular reference to increasing 
research transparency. Our original article did not purport to include a comprehensive review; rather, it 
is an opinion piece written largely from the experience and perspective of the authors. We agree that 
there may be other benefits to model replication and that further exploration of these may be valuable. 
However, we consider that model replication is neither an efficient nor effective means of promoting 
research transparency in modelling studies ± in our view, this goal is more likely to be achieved by 
subjecting original model analyses to more rigorous reporting standards, and ideally, by establishing 
processes in which original models are made openly accessible to other potential model users, thereby 
bypassing the need for replication entirely. We believe that the responsibility for increasing research 
transparency lies with the original model developer, not the model replicator. 
 
McManus et al. also dispute one of the caveats of model replication described in our article: namely, 
wrongfully assuming that the existing model structure is suitable to address the current decision problem 
at hand. It is suggested that this may be more of a failure on the part of the modeller rather than a failure 
of model replication process. Regardless of whether this issue rests with the model replicator, or the 
process by which the candidate model is selected, this remains an important caveat that should be 
considered before pursuing the replication of any model. McManus et al. also point out that the selection 
criteria for our pilot study were not sufficiently clear: we included the latest five economic analyses 
published in Pharmacoeconomics at the time we started working on our pilot study. Whilst it is not 
possible to have a fully random sample of modelling studies, excluding Tappenden et al. [3] and 
selecting a different study in its place would have introduced an additional non-random element into 
our sample. The key finding of the pilot study was that most of the models attempted could not be 
replicated by the authors, and for those which could be replicated, discrepancies in the results were 
evident. The specific models which could be replicated, and those that could not, are irrelevant to this 
conclusion. It is also suggested that we might have harmed the validity of our pilot study by influencing 
the replication of the Tappenden et al. UC model. As stated in the article, this model was replicated in 
isolation by a different author. We agree however that other modellers might produce more or less 
discrepant results when attempting to replicate the models reported by Tappenden et al. [3] and 
Versteegh et al [4]. McManus et al. comment that the MS pilot study by Versteegh et al.[4] was 
replicated from a previous model (Bell et al. [5]) and that the difficulties in replication encountered in 
their replication exercise were not explored. Our objective was to replicate the analysis reported by 
Versteegh et al., not the earlier model by Bell et al., hence this criticism is not relevant to our pilot 
study. 
 
:HDJUHHWKDWWKHQRWLRQRIµVXFFHVVIXOUHSOLFDWLRQ¶ZDVQRWH[SOLFLWO\GHILQed. In our pilot study, we 
considered that the replication was successful if: (a) all the necessary information to replicate the model 
was available, and (b) if the results were not significantly dissimilar from the original reported model 
results. McManus et al. also criticise the paper for failing to provide the results of the replicated models 
versus the original study results. As indicated in the manuscript, the replicated case study models are 
available upon request and readers are welcome to make their own judgements about the significance 
of the discrepancies found in our results. For clarity, we report here the percentage differences between 
the results of our replicated models and the original reported analyses. For the UC model, the difference 
between the original and replicated QALYs for the five interventions was less than 0.36%, whilst the 
difference between original and replicated costs was 1-4%. Excluding colectomy, which dominated all 
other options, the deterministic ICERs were 9.6% and 1% lower than the reported ICERs for 
adalimumab and infliximab, respectively. For the MS model, all seven replicated ICERs indicated a 
deviation in ICERs of around 17% compared with the original reported results. We agree that the Philips 
et al. checklist [7] represents a more comprehensive basis for critiquing health economic models and 
that its use may further improve transparency in model reporting, particularly in terms of the adopted 
methodology, but note that adopting multiple checklists would increase the burden for publishers. 
Despite some points of disagreement, overall, we agree with McManus et al. that there are few 
publications specifically on the role and value of model replication and that there is scope to further 
explore this topic.  
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